Illumina Inc - Company Profile
Powered by 
All the sales intelligence you need on Illumina Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Illumina Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Illumina Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and cancer. The company's products include sequencing kits and reagents, sequencing tools and systems, microarray kits and reagents, molecular biology reagents, and arrays and reagents. Illumina also offers services such as whole-genome sequencing, genotyping, NIPT, microarray services, instrument services, training, consulting, and product support services. It offers products to genomic research centers; academic institutions; government laboratories; hospitals; and pharmaceutical, biotechnology, commercial molecular diagnostic laboratories; and consumer genomics companies in the Americas, Europe, and the Asia-Pacific. It operates manufacturing facilities in the US, Singapore, the UK, the Netherlands, China, and India. Illumina is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
5200 Illumina Way, San Diego, California, 92122
Website
www.illumina.com
Telephone
1 858 2024500
No of Employees
8,600
Industry
Medical Equipment
Ticker Symbol & Exchange
ILMN (NASD)
Revenue (2024)
$4.3B
-0.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
169.5%
(2024 vs 2023)
Market Cap*
$27.8B
Net Profit Margin (2024)
XYZ
170.0%
(2024 vs 2023)
* As of and is in US$
Illumina Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Sequencing Platforms | Instrument Services | Illumina |
| Microarray Scanners | Informatics Services | Assign |
| IVD Instruments | Sequencing Services | Ampligase |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In June, the company introduced the StrataMap Spatial Solution. |
| 2026 | New Products/Services | In My, the company and SPT Labtech launched the fireflyGO automation platform. |
| 2026 | Contracts/Agreements | In April, the company entered into a partnership with the Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare diseases. |
Competitor Comparison
| Key Parameters | Illumina Inc | Thermo Fisher Scientific Inc | Agilent Technologies Inc | Qiagen NV | Oxford Nanopore Technologies Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Netherlands | United Kingdom |
| City | San Diego | Waltham | Santa Clara | Venlo | Oxford |
| State/Province | California | Massachusetts | California | - | Greater London |
| No. of Employees | 8,600 | 125,000 | 17,900 | 5,526 | 1,300 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jacob Thaysen, PhD | Director; Interim Chief Commercial Officer; Chief Executive Officer | Executive Board | 2023 | 50 |
| Ankur Dhingra | Chief Financial Officer | Senior Management | 2024 | 50 |
| Mark Field | Chief Information Officer | Senior Management | 2025 | - |
| Steven Barnard, PhD | Chief Technology Officer | Senior Management | 2023 | 65 |
| Scott Davies | General Counsel; Chief Legal Officer | Senior Management | 2025 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer